Actively Recruiting
A Non-Interventional Pragmatic Clinical Trial of NLP Models for the Detection of Immune-Related Adverse Events to Improve Biorepository Registration
Led by Brigham and Women's Hospital · Updated on 2025-06-19
100
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
Sponsors
B
Brigham and Women's Hospital
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating if an automated informatics system can improve the detection and registration of immune-related adverse events (irAEs) in patients receiving immunotherapy for cancer. The study aims to see whether this system is feasible for daily use and if it increases registration rates to a specialized irAE biorepository compared to standard monitoring methods. This trial is a randomized controlled study conducted at a single institution, focusing on patients with malignancy receiving immuno-oncology treatments. Participants will be randomly assigned to either standard irAE monitoring, where treating clinicians report eligible events, or to informatics-assisted monitoring, which includes a daily automated review of electronic health records (EHR) using the informatics system. The system runs behind the institution's secure firewall, identifying patients with new irAEs for potential registration in the biorepository. The study includes a feasibility run-in with the first 10-20 patients and plans to enroll about 100 participants in total. During the study, patients' EHRs will be reviewed to collect demographic, medical, and cancer treatment information. Participants will be monitored for irAEs for up to 12 months or until they register in the biorepository. Researchers will assess the feasibility of daily EHR analysis, registration rates, time to data entry after irAEs, and the accuracy of irAE detection based on expert review. The study will use a triple-masked randomized design to compare outcomes between the two monitoring methods.
CONDITIONS
Brief Title
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Received or currently receiving a regimen containing one or more immuno-oncology therapeutics
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants are randomized to either standard immune-related adverse event (irAE) monitoring or informatics-assisted irAE monitoring to detect eligible registration events for the biorepository.
Participants remain under continuous monitoring through electronic health records with periodic reviews by study staff; no additional in-person visits required
Duration - Up to 12 months
Participants are observed for registration onto the biorepository and data entry related to irAE detection during this period.
No additional visits; data collection occurs remotely through the informatics system and clinical records
Trial Site Locations
Total: 2 locations
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
D
Danielle Bitterman, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here